Showing 1921-1930 of 9078 results for "".
How do barrier dysfunction proteins interact with immune dysregulation to sustain AD?
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/how-do-barrier-dysfunction-proteins-interact-with-immune-dysregulation-to-sustain-ad/56736/Raj Chovatiya, MD, PhD, MSCI, FAAD, discusses whether barrier dysfunction drives inflammation and immune dysregulation, or vice versa, or both, in atopic dermatitis.New Clinical Guidelines for Nonmelanoma Skin Cancer Treatment; Arctics Biotherapeutics Seeks New FDA Approval for ZORYVE Foam
https://practicaldermatology.com/series/dermwire-tv/new-clinical-guidelines-for-nonmelanoma-skin-cancer-treatment-arctics-biotherapeutics-seeks-new-fda-approval-for-zoryve-foam/26745/In this week’s DermwireTV, new clinical guidelines for nonmelanoma skin cancer treatment; Arcutis Biotherapeutics seeks new FDA approval for ZORYVE foam; Practical Dermatology joins the ReachMD network; and the CEO of SofWave Medical joins us to discuss the company’s Ultrasound technology.Part 3, 1726 nm lasers: How to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is to be patient
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24341/Chapter 3 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is toPart 4, 1726 nm lasers: Handling referred patients who are already on different treatment regimens
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24342/Chapter 4 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about handling referred patients who are already on different treatment regimens.Part 7, 1726 nm lasers: When a patient doesn’t improve: Doctors discuss “pearls” of wisdom
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24345/Chapter 7 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about when a patient doesn’t improve: Doctors discuss “pearls” of wisdom.Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
https://practicaldermatology.com/series/dermwire-tv/study-examines-association-between-childhood-bmi-and-risk-of-developing-imsds/27004/In this week's DermwireTV, a new study examines the relationship between childhood BMI and skin diseases; phase 3 data sheds new light on dupilumab’s effect on inflammatory biomarkers in pediatric AD patients; and the president and CEO of Evolus discusses trends in the injectables market.DWTV Extra: GPP Awareness Day
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-gpp-awareness-day/36704/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, discusses the importance of educating more clinicians about generalized pustular psoriasis (GPP) and observing GPP Awareness Day on August 13.FDA Approval for Delgocitinib
https://practicaldermatology.com/series/c-suite-chats/fda-approval-for-delgocitinib/36650/Robert Spurr, EVP, North America for LEO Pharma, discusses the importance of an FDA-approved option for treating moderate-to-severe chronic hand eczema in adults.DWTV Extra: New Tapinarof Data for AD
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-new-tapinarof-data-for-ad/33940/Linda Stein Gold, MD, discusses the results from the Phase 3 ADORING 3 open-label, long-term extension study evaluating tapinarof cream, 1% once daily in children as young as 2 and adults with atopic dermatitis, presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in OrlandoNew Treatment Option for Androgenetic Alopecia
https://practicaldermatology.com/series/c-suite-chats/new-treatment-option-for-androgenetic-alopecia/32969/Reid Waldman, MD, Co-Founder and CEO of Veradermics, discusses the prevalence of androgenetic alopecia-pattern hair loss and the company's investigational treatment candidate.